Search results
Results from the WOW.Com Content Network
XLR-11 (5"-fluoro-UR-144 or 5F-UR-144) is a drug that acts as a potent agonist for the cannabinoid receptors CB 1 and CB 2 with EC 50 values of 98 nM and 83 nM ...
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the ...
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. [3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University .
An analog of oleoylethanolamide, the endogenous agonist for proliferator-activated receptor α . It also acts as a weak cannabinoid agonist. AM-4030: 0.7: 8.6: CB 1 (12×) 6.17: A potent agonist at both CB 1 and CB 2, it is dodecally selective for CB 1. It is a derivative of HU-210 and represents a hybrid structure between the classical and ...
O-1602 is a synthetic compound most closely related to abnormal cannabidiol, and more distantly related in structure to cannabinoid drugs such as THC.O-1602 does not bind to the classical cannabinoid receptors CB 1 or CB 2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55.
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids (THC, CBD and many others) in cannabis plants attach. [1] These novel psychoactive substances should not be confused with synthetic phytocannabinoids (obtained by chemical synthesis ) or synthetic endocannabinoids from which they ...
5F-CUMYL-PINACA (also known as SGT-25 and sometimes sold in e-cigarette form as C-Liquid) [1] is an indazole-3-carboxamide based synthetic cannabinoid. [2] 5F-CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with the original patent claiming approximately 4x selectivity for CB 1, having an EC 50 of <0.1 nM for human CB 1 receptors and 0.37 nM for human CB 2 receptors. [3]
Compared to THC, which is a partial agonist at CB 1 receptors, JWH-018, and many synthetic cannabinoids, are full agonists. JWH-018 may cause intense anxiety, agitation, and in rare cases, has been assumed to have been the cause of seizures and convulsions. JWH-018 and analogs of it may present serious dangers to the user when used to excess. [22]